4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: May 10, 2023
Period of Report: May 9, 2023
Accession Number: 0001968202-23-000013

View Document ↗ View on SEC.gov ↗